The latest results involving an experimental drug have some promising findings when it comes to treating Alzheimer's Disease. Phase 3 trial data shows lecanemab after 18 months was associated with more clearance of amyloid and less cognitive decline.

While the findings offer hope, they also raise safety concerns because of the drug's association with some serious adverse effects. Susan Howland is program director of the Alzheimer's Association California Southland chapter. And Tony Gonzales is an Alzheimer’s Association National Early-Stage Advisor. He was diagnosed with mild cognitive impairment at age 47 last year.   

The latest results involving an experimental drug have some promising findings when it comes to treating Alzheimer's Disease. Phase 3 trial data shows lecanemab after 18 months was associated with more clearance of amyloid and less cognitive decline.
While the findings offer hope, they also raise safety concerns because of the drug's association with some serious adverse effects. Susan Howland is program director of the Alzheimer's Association California Southland chapter. And Tony Gonzales is an Alzheimer’s Association National Early-Stage Advisor. He was diagnosed with mild cognitive impairment at age 47 last year.

Advertisement